Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2013 Mar 3;71(5):1231–1240. doi: 10.1007/s00280-013-2117-x

Fig. 5.

Fig. 5

Biomarker expression in tumors at the end of the 5-week dosing regimen of everolimus (1 mg/kg), sorafenib (20 mg/kg), the 2-drug combination (everolimus 1 mg/kg and sorafenib 20 mg/kg), or placebo. a VEGFR2. b Ratio of pERK to total ERK. c Ratio of pAKT to total AKT